Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers
Benjamina Esapa, Jiexuan Jiang, Anthony Cheung, et al.
Cancers (2023) Vol. 15, Iss. 6, pp. 1845-1845
Open Access | Times Cited: 44

Showing 26-50 of 44 citing articles:

Chondroitin Sulfate Proteoglycan 4 (CSPG4) as an Emerging Target for Immunotherapy to Treat Melanoma
Xinyi Chen, Shabana Habib, Madalina Alexandru, et al.
Cancers (2024) Vol. 16, Iss. 19, pp. 3260-3260
Open Access | Times Cited: 2
Emerging conjugation strategies and protein engineering technologies aim to improve ADCs in the fight against cancer
Eric J. Moore, M. S. Rice, Gourgopal Roy, et al.
Xenobiotica (2024) Vol. 54, Iss. 8, pp. 469-491
Open Access | Times Cited: 2
The journey of antibody-drug conjugates for revolutionizing cancer therapy: A review
Fatima Akram, Amna M. Ali, Muhammad Tayyab Akhtar, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 117, pp. 118010-118010
Closed Access | Times Cited: 2
Pioneering the Way: The Revolutionary Potential of Antibody–Drug Conjugates in NSCLC
Xiehui Chen, Changchun Zeng
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 4, pp. 556-584
Closed Access | Times Cited: 1
Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy
Ari J. Rosenberg, Cesar A. Perez, Wenji Guo, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 1
Update of antibody–drug conjugates for hematological malignancies
Wenyue Sun, Shunfeng Hu, Xin Wang
Current Opinion in Oncology (2024) Vol. 36, Iss. 5, pp. 430-436
Closed Access | Times Cited: 1
Beyond Cytotoxic Potency: Disposition Features Required to Design ADC Payload
Hao Sun, Larry C. Wienkers, Anthony Lee
Xenobiotica (2024) Vol. 54, Iss. 8, pp. 442-457
Closed Access | Times Cited: 1
Expanding the repertoire of Antibody Drug Conjugate (ADC) targets with improved tumor selectivity and range of potent payloads through in-silico analysis
Umesh Kathad, Neha Biyani, Raniero L. Peru y Colón De Portugal, et al.
PLoS ONE (2024) Vol. 19, Iss. 8, pp. e0308604-e0308604
Open Access | Times Cited: 1
Antibody-Drug Conjugates in Breast Cancer: Toward a Molecular Perspective Into Clinical Practice
Roberto Paz-Manrique, Joseph A. Pinto, Guillermo Valencia
JCO Precision Oncology (2024), Iss. 8
Closed Access | Times Cited: 1
Antibody–drug conjugates as targeted therapy for treating gynecologic cancers: update 2025
Jordyn Silverstein, Beth Y. Karlan, Nasim Herrington, et al.
Current Opinion in Obstetrics & Gynecology (2024)
Closed Access | Times Cited: 1
Navigating the Future: Advancements in Monoclonal Antibody Nanoparticle Therapy for Cancer
Harshad S. Kapare, Mayuri Bhosale, Ritesh P. Bhole
Journal of Drug Delivery Science and Technology (2024) Vol. 104, pp. 106495-106495
Closed Access | Times Cited: 1
Antibody drug conjugates in recurrent or metastatic cervical cancer: a focus on tisotumab vedotin state of art
Floriana Camarda, Mariachiara Paderno, Maria Chiara Cannizzaro, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access
Macropinocytosis-targeted peptide-docetaxel conjugate for bystander pancreatic cancer treatment
Young Seok Cho, Hanhee Cho, Ha Rin Kim, et al.
Journal of Controlled Release (2024) Vol. 376, pp. 829-841
Closed Access
Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy
Rositsa Mihaylova, Denitsa Momekova, Viktoria Elincheva, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 12, pp. 1701-1701
Open Access
Clinical and Immunologic Characteristics of Colorectal Cancer Tumors Expressing LY6G6D
Adrián Sanvicente García, Manuel Pedregal, Lucía Paniagua‐Herranz, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5345-5345
Open Access
Advances in Cancer Treatment: Harnessing Antibody-Drug Conjugates and Oncolytic Viruses for Targeted Therapy

American Journal of Pure and Applied Biosciences (2024), pp. 169-175
Open Access
Meta‐Analysis of Exposure‐Adverse Event Relationships for Antibody–Drug Conjugates
Cheng Wang, Linda Irons, Holly Kimko, et al.
The Journal of Clinical Pharmacology (2024)
Open Access
Concise access to C2-ethylidene pyrrolo[1,4]benzodiazepine natural products
Zigmārs Leitis, Guna Sakaine, Katrīna Brokāne, et al.
Organic & Biomolecular Chemistry (2023) Vol. 21, Iss. 45, pp. 9061-9064
Closed Access
Illuminating underappreciated mechanisms of receptor regulation in human lymphocytes.
Cassandra Woolley
(2023)
Open Access
Previous Page - Page 2

Scroll to top